Jbm (Healthcare) Ltd banner

Jbm (Healthcare) Ltd
HKEX:2161

Watchlist Manager
Jbm (Healthcare) Ltd Logo
Jbm (Healthcare) Ltd
HKEX:2161
Watchlist
Price: 2.76 HKD 1.47% Market Closed
Market Cap: HK$2.3B

Relative Value

The Relative Value of one Jbm (Healthcare) Ltd stock under the Base Case scenario is 2.14 HKD. Compared to the current market price of 2.76 HKD, Jbm (Healthcare) Ltd is Overvalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
2.14 HKD
Overvaluation 22%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Jbm (Healthcare) Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
Jbm (Healthcare) Ltd
HKEX:2161
2.2B HKD 2.8 10.4 9 9
US
Eli Lilly and Co
NYSE:LLY
932.7B USD 14.3 45.2 30.5 32.5
US
Johnson & Johnson
NYSE:JNJ
575.4B USD 6.1 21.6 15 18.4
CH
Roche Holding AG
SIX:ROG
280.7B CHF 4.6 30 12.7 14.8
CH
Novartis AG
SIX:NOVN
241.3B CHF 5.5 22.1 13.7 17.6
UK
AstraZeneca PLC
LSE:AZN
232.7B GBP 5.3 30.3 16.8 23.6
US
Merck & Co Inc
NYSE:MRK
289.2B USD 4.5 15.9 9.9 12
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.8 8 9.3
US
Pfizer Inc
NYSE:PFE
149.2B USD 2.4 19.4 7.5 10
US
Bristol-Myers Squibb Co
NYSE:BMY
122.5B USD 2.6 17.5 7.3 9
P/E Multiple
Earnings Growth PEG
HK
Jbm (Healthcare) Ltd
HKEX:2161
Average P/E: 22.3
10.4
18%
0.6
US
Eli Lilly and Co
NYSE:LLY
45.2
28%
1.6
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
CH
Roche Holding AG
SIX:ROG
30
29%
1
CH
Novartis AG
SIX:NOVN
22.1
15%
1.5
UK
AstraZeneca PLC
LSE:AZN
30.3
26%
1.2
US
Merck & Co Inc
NYSE:MRK
15.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
7%
1.5
US
Pfizer Inc
NYSE:PFE
19.4
26%
0.7
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
Jbm (Healthcare) Ltd
HKEX:2161
Average EV/EBITDA: 43.2
9
15%
0.6
US
Eli Lilly and Co
NYSE:LLY
30.5
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
CH
Novartis AG
SIX:NOVN
13.7
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
16.8
13%
1.3
US
Merck & Co Inc
NYSE:MRK
9.9
3%
3.3
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
2%
4
US
Pfizer Inc
NYSE:PFE
7.5
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-10%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett